SHENZHEN, China, Dec. 8, 2025 /PRNewswire/ -- PCBAIR announced the launch of its advanced 8-layer Glass Core PCB manufacturing capabilities, combining proprietary Through Glass Via (TGV) technology with multi-layer redistribution layers (RDL). The new glass substrates achieve superior signal integrity and thermal stability, addressing the critical interconnect density limitations faced by traditional organic substrates in the era of artificial intelligence and high-performance computing (HPC).
Designed for AI accelerators, high-speed data center servers, and optical transceivers, PCBAIR's 8-layer Glass Core PCBs support finer line widths and spacing, with pilot production and customer sampling commencing immediately.
PCBAIR developed this high-density interconnect solution through specific innovations in glass processing, metallization, and stacking. Each technical improvement contributes to the reduction of signal loss and the enhancement of mechanical reliability:
Altogether, these improvements enable chip designers to bypass current packaging bottlenecks, allowing for higher performance scaling without the exponential cost increase associated with traditional silicon interposers.
"We are proud to introduce our 8-layer Glass Core PCB capabilities, marking a practical step forward in advanced packaging," said Victor Zhang, a technology expert and the chief technology officer of PCBAIR. Zhang, whose technical insights have been recognized by major media outlets such as Forbes, added, "By moving from organic to glass cores, we are providing a stable foundation for the industry's most demanding compute workloads, maintaining the precision and reliability our partners expect."
PCBAIR's Glass Core PCBs are also fully compatible with existing substrate assembly lines, ensuring a smoother transition for customers looking to adopt glass-based technology. The company offers a turnkey solution, handling the delicate manufacturing and assembly processes required for glass substrates to mitigate supply chain risks for its global clients.
About PCBAIR
Established in 2014, PCBAIR is a leading PCB manufacturer and assembly service provider dedicated to high-reliability electronics. With over a decade of expertise, the company provides a seamless one-stop solution ranging from rapid prototyping to high-volume manufacturing. PCBAIR's services include PCB fabrication, component sourcing, and turnkey assembly. The company is certified to IATF 16949, ISO 13485, and ISO 9001, and adheres to IPC-A-610 and J-STD-001 standards. The company also ensures full environmental and safety compliance via UL, RoHS, and REACH certifications. For more information, visit www.pcbair.com.
For media inquiries, please contact:
Cyndi
Marketing Manager
Email: Inquiry@pcbair.com
Website: https://www.pcbair.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
PCBAIR Unveils 8-Layer Glass Core PCB Manufacturing for Next-Gen AI & HPC
|
SOMERSET, N.J., March 3, 2026 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a global contract research organization specializing in strategic planning for clinical development and cross‑border clinical trial solutions and services, concluded a successful presence at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
HiRO's Founder and CEO, Dr. Karen Chu, was a featured speaker at RESI JPM, where she moderated a panel convening investors and strategics at the forefront of the cell and gene therapy revolution. Panelists Robert Balfour of ALSA Ventures and Bettina Ernst of BERNINA BioInvest highlighted the current momentum in cell and gene therapies, discussed how they assess technical and commercial risk, identified partnership models that accelerate progress, and outlined where capital is flowing in this rapidly advancing field.
Dr. Chu also led a workshop titled "Leveraging Asia: How to Navigate Asian VC Investment Mandates." The session opened with the 2026 industry outlook and key trends, then highlighted priority therapeutic areas. It explained the NewCo model and the criteria Asian venture capital firms use to evaluate global biotech assets, their co‑investment preferences, and expectations for commercialization. The workshop featured Asia‑based investors Dr. Alva Chen, Managing Director and Head of Therapeutics, VMS Group; Jayson Lee, Partner and Head of Healthcare Investing, LongRiver Investments; and Dr. Maomeng Tong, Principal, INCE Capital, who shared strategic insights for biotechs pursuing cross‑border capital or collaboration.
"Asia's steady capital recovery is fueling more diverse, higher-quality biotech deals. Investors are increasingly favoring more scalable, capital-efficient, innovative business models. One such emerging approach is the NewCo model, which combines equity participation with experienced management teams, leverages Asia's efficient clinical speed and ecosystem partners to accelerate data generation, and enables program-level co-development. These elements de-risk global development in multiple ways, making the opportunities more attractive for international syndicates," said Dr. Alva Chen, Managing Director and Head of Therapeutics, VMS Group.
"Clinical development now spans multiple regions more than ever and requires an integrated strategy. HiRO's cross‑border capabilities across APAC, the US, and Europe allow us to align regulatory strategy, site selection, and operational execution to bridge data across regions, accelerate timelines, and reduce redundant costs. By leveraging local expertise, regional cost advantages, and selective partnerships, we help biotech sponsors generate earlier, higher‑quality readouts and deploy capital more efficiently to advance financing and licensing goals," said Dr. Karen Chu, Founder and CEO of HiRO.
About Harvest Integrated Research Organization (HiRO)
Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization. With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services.
As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide. For more information on HiRO, please visit www.harvestiro.com.
SOMERSET, N.J., March 3, 2026 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a global contract research organization specializing in strategic planning for clinical development and cross‑border clinical trial solutions and services, concluded a successful presence at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
HiRO's Founder and CEO, Dr. Karen Chu, was a featured speaker at RESI JPM, where she moderated a panel convening investors and strategics at the forefront of the cell and gene therapy revolution. Panelists Robert Balfour of ALSA Ventures and Bettina Ernst of BERNINA BioInvest highlighted the current momentum in cell and gene therapies, discussed how they assess technical and commercial risk, identified partnership models that accelerate progress, and outlined where capital is flowing in this rapidly advancing field.
Dr. Chu also led a workshop titled "Leveraging Asia: How to Navigate Asian VC Investment Mandates." The session opened with the 2026 industry outlook and key trends, then highlighted priority therapeutic areas. It explained the NewCo model and the criteria Asian venture capital firms use to evaluate global biotech assets, their co‑investment preferences, and expectations for commercialization. The workshop featured Asia‑based investors Dr. Alva Chen, Managing Director and Head of Therapeutics, VMS Group; Jayson Lee, Partner and Head of Healthcare Investing, LongRiver Investments; and Dr. Maomeng Tong, Principal, INCE Capital, who shared strategic insights for biotechs pursuing cross‑border capital or collaboration.
"Asia's steady capital recovery is fueling more diverse, higher-quality biotech deals. Investors are increasingly favoring more scalable, capital-efficient, innovative business models. One such emerging approach is the NewCo model, which combines equity participation with experienced management teams, leverages Asia's efficient clinical speed and ecosystem partners to accelerate data generation, and enables program-level co-development. These elements de-risk global development in multiple ways, making the opportunities more attractive for international syndicates," said Dr. Alva Chen, Managing Director and Head of Therapeutics, VMS Group.
"Clinical development now spans multiple regions more than ever and requires an integrated strategy. HiRO's cross‑border capabilities across APAC, the US, and Europe allow us to align regulatory strategy, site selection, and operational execution to bridge data across regions, accelerate timelines, and reduce redundant costs. By leveraging local expertise, regional cost advantages, and selective partnerships, we help biotech sponsors generate earlier, higher‑quality readouts and deploy capital more efficiently to advance financing and licensing goals," said Dr. Karen Chu, Founder and CEO of HiRO.
About Harvest Integrated Research Organization (HiRO)
Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization. With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services.
As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide. For more information on HiRO, please visit www.harvestiro.com.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment
